7:30AM Bacterin International's OsteoSponge product generates 'positive' clinical results (BONE) 1.42 : Co announces that the first clinical results using the OsteoSponge product for foot and ankle arthrodesis have been published in "The Journal of Foot & Ankle Surgery." The article reports a multi-center, retrospective analysis of 80 joint fusions in 47 subjects who had undergone foot and ankle fusion procedures utilizing OsteoSponge bone graft. Overall, a fusion rate of 97.5% (78 of 80 joints) was determined by radiographic analysis.
The article reported comparable or greater foot and ankle fusion rates, as judged radiographically, to that reported in the biomedical literature. Additionally, at 12-month post-operative assessment, the authors observed statistically significant improvements in function and pain alleviation at rates greater than those previously reported in biomedical studies.
The article reported comparable or greater foot and ankle fusion rates, as judged radiographically, to that reported in the biomedical literature. Additionally, at 12-month post-operative assessment, the authors observed statistically significant improvements in function and pain alleviation at rates greater than those previously reported in biomedical studies.
Recent XTNT News
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/29/2026 08:05:06 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/13/2026 11:33:08 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 11:15:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:05:34 AM
- Xtant Medical Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/13/2026 11:00:00 AM
- Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026 • PR Newswire (US) • 05/07/2026 12:00:00 PM
- Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped • PR Newswire (US) • 05/06/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 01:20:24 PM
- Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product • PR Newswire (US) • 04/13/2026 01:04:00 PM
- Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial • PR Newswire (US) • 04/09/2026 12:00:00 PM
- Xtant Medical shares drop nearly 5% as weak 2026 outlook overshadows Q4 beat • IH Market News • 03/31/2026 02:54:42 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 11:16:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:05:23 AM
- Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:00:00 AM
- Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026 • PR Newswire (US) • 03/25/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 01:15:49 PM
- Xtant Medical Finalizes Companion Spine Transactions • PR Newswire (US) • 03/02/2026 01:00:00 PM
- Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference • PR Newswire (US) • 02/25/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 10:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 09:15:32 PM
- Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft • PR Newswire (US) • 12/11/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2025 09:05:52 PM

